Metformin in polycystic ovary syndrome

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 6, 2004, Pages 481-486

  Lord, Jonathan ^a   Wilkin, Terry ^b  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Metabolic syndrome; Metformin; Ovulation induction; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; CLOMIFENE; GONADOTROPIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; ANTIDIABETIC AGENT; FERTILITY PROMOTING AGENT;

ANOVULATION; CLINICAL TRIAL; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; DIET; DRUG EFFICACY; EXERCISE; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MULTIPLE PREGNANCY; OBESITY; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; BODY WEIGHT; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG COMBINATION; FEMALE;

ANOVULATION; BODY WEIGHT; CLOMIPHENE; DRUG THERAPY, COMBINATION; FEMALE; FERTILITY AGENTS, FEMALE; GLUCOSE METABOLISM DISORDERS; GONADOTROPINS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME;

EID: 16644381519     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200412000-00008     Document Type: Review

References (52)

1. Dhindsa G, Bhatia R, Dhindsa M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004; 50:140-144. A recent review article that provides a useful summary of the endocrinology of PCOS, and what is understood of its aetiology.
2. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24:633-667.
3. The Rotterdam ESHRE-ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47. An international consensus paper that reviewed the evidence on the criteria used to diagnose PCOS, and produced revised guidelines to standardize the diagnostic criteria for the benefit of patients, clinicians and researchers.
4. Balen AH, Laven JSE, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9:505-514. A detailed literature review summarizing the ultrasound characteristics of the polycystic ovary. This was presented at the joint ASRM/ESHRE consensus meeting on PCOS that led to the new international consensus definition of PCOS.
5. Royal College of Obstetricians and Gynaecologists. Long-term consequences of polycystic ovary syndrome. Clinical Green Top Guidelines, vol. 33; 2003. London: RCOG.
6. Norman RJ, Wu R, Stankiewicz MT. Polycystic ovary syndrome. Med J Aust 2004; 180:132-137. One of the best general reviews that covers all aspects of PCOS. Freely available on-line.
7. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876-1880.
8. Balen A. Ovulation induction: optimizing results and minimizing risks. Hum Fertil (Camb) 2003; 6:S42-S51. A comprehensive and detailed review of the literature relating to ovulation induction arising from the proceedings of a joint meeting of the Royal College of Obstetricians and Gynaecologists and the British Fertility Society, 'The development of a national service framework for infertility services in the UK'.
9. Tsilchorozidou T, Prelevic GM. The role of metformin in the management of polycystic ovary syndrome. Curr Opin Obstet Gynecol 2003; 15:483-488.
10. Moran LJ, Noakes M, Clifton PM, et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 2004; 89:3337-3344.
11. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951-953.
12. Cheang KI, Nestler JE. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 2004; 8:440-447.
13. Vanky E, Salvesen KA, Carlsen SM. Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. Hum Reprod 2004; 19:529-533.
14. Barbieri RL, Gargiulo AR. Metformin for the treatment of the polycystic ovary syndrome. Minerva Ginecol 2004; 56:63-79.
15. Saleh AM, Khalil HS. Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2004; 83:614-621.
16. National Institute for Clinical Excellence. Fertility assessment and treatment for people with fertility problems: full guideline. 1st ed. London: Royal College of Obstetricians and Gynaecologists; 2004. The most authoritative review of evidence for the management of infertile couples. NICE produces the guidance as recommendations for the UK health service. Freely available on-line as a detailed guideline (216 pages), summary guideline, management algorithm, notes for patients and economic modelling.
17. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003. A detailed metaanalysis of the RCTs involving insulin sensitizers in PCOS. As with all Cochrane reviews, it will be updated regularly. Available on-line (free in many countries).
18. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60:241-249. An RCT with four arms comparing placebo, metformin, flutamide and combined metformin and flutamide. It reported that the combination therapy gave the greatest metabolic benefits. The combination of antiandrogen agents and insulin sensitizers is opening a new field of investigation in PCOS research. The trial also suggested that dieting was the most important factor in reducing insulin resistance.
19. George SS, George K, Irwin C, et al. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003; 18:299-304.
20. Maciel GA, Soares Junior JM, ves da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004; 81:355-360.
21. Ramzy A-M, Al-Inany H, Aboulmaaty Z, et al. The use of metformin in overweight and lean infertile patients with polycystic ovarian syndrome: a randomized controlled trial. Middle East Peril Soc J 2003; 8:143-149.
22. Sahin Y, Yirmibes U, Kelestimur F, Aygen E. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 113:214-220.
23. Chou KH, von Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003; 35:86-91.
24. Malkawi HY, Qublan HS, Hamaideh AH. Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. J Obstet Gynaecol 2003; 23:289-293.
25. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:2767-2774.
26. Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52:908-915.
27. Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med 2004; 49:361-367.
28. Kazerooni T, Dehghan K. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17:51-56.
29. Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81:114-119.
30. Pawelczyk L, Spaczynski RZ, Banaszewska B, Duleba AJ. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 113:209-213.
31. Hahn S, Quadbeck B, Eisenbruch S, et al. Metformin, an efficacious drug in the treatment of polycystic ovary syndrome [in German]. Dtsch Med Wochenschr 2004; 129:1059-1064.
32. Gonzalez-Gonzalez F, Nicolau O, Essien J, Bardales J. The effect of metformine chloryhydrate on the metabolism of women with polycystic ovary syndrome [in Spanish]. Clin Invest Gin Obst 2003; 30:78-85.
33. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:4649-4654. An interesting RCT with four arms comparing metformin with combined oral contraceptive in both obese and nonobese women. It reported that metformin improved C-reactive protein levels in marked contrast to the combined pill, although this may have been secondary to changes in fat distribution.
34. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13:251-257.
35. Female infertility: treatment options for complicated cases. The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. Hum Reprod 1997; 12:1191-1196.
36. Tasdemir S, Ficicioglu C, Yalti S, et al. The effect of metformin treatment to ovarian response in cases with PCOS. Arch Gynecol Obstet 2004; 269:121-124.
37. Fedorcsak P, Dale PO, Storeng R, et al. The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecol Endocrinol 2003; 17:207-214.
38. Kjotrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome: a prospective, randomized, double blind study. Hum Reprod 2004; 19:1315-1322.
39. Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic. The International Diabetes Federation Consensus Workshop. Diabetes Care 2004; 27:1798-1811.
40. Simmons D, Walters BN, Rowan JA, McIntyre HD. Metformin therapy and diabetes in pregnancy. Med J Aust 2004; 180:462-464. A report from the Australian Diabetes in Pregnancy Society working party that presents a consensus view on the use and safety of metformin in pregnancy. Freely available on-line.
41. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004; 19:1323-1330.
42. Vanky E, Salvesen KA, Heimstad R, et al. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004, 19:1734-1740.
43. Norman RJ, Wang JX, Hague W. Should we continue or stop insulin sensitizing drugs during pregnancy? Curr Opin Obstet Gynecol 2004; 16:245-250.
44. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence: a therapeutic conundrum. Hum Reprod 2004; 19:1039-1042. A review on the contentious topic of the use of metformin in teenagers that presents the controversy with careful reference to the available evidence.
45. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004; 89:2756-2762.
46. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-merformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89:1592-1597.
47. Driscoll D. Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci 2003; 997:49-55.
48. Harborne L, Fleming R, Lyall H, et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:4116-4123. A well designed RCT reporting that metformin was an effective treatment in the management of hirsutism in women with PCOS, despite the fact that it did not significantly reduce androgen levels.
49. Glueck CJ, Moreira A, Goldenberg N, et al. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18:1618-1625.
50. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79:562-566.
51. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003; 10:99-104.
52. Tarrade A, Schoonjans K, Pavan L, et al. PPARγ/RXRα heterodimers control human trophoblast invasion. J Clin Endocrinol Metab 2001; 86:5017-5024.